Chipscreen Biosciences, Ltd.
48
10
11
27
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
4.2%
2 terminated/withdrawn out of 48 trials
93.1%
+6.6% vs industry average
21%
10 trials in Phase 3/4
0%
0 of 27 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (48)
A Study of Chiglitazar in Patients With Metabolic Dysfunction-associated Steatohepatitis and Type 2 Diabetes Mellitus
Role: collaborator
A Phase Ⅰ Study of CS08399 in Participants With MTAP-deleted Solid Tumors and Lymphoma
Role: lead
Chiglitazar Added to SGLT-2 Inhibitors for Type 2 Diabetes
Role: lead
A Study of Tucidinostat Combined With Tislelizumab as First-line Treatment in Advanced NSCLC
Role: lead
Bioequivalence Study of Chiglitazar/Metformin Extended-Release Tablets
Role: lead
Phase III Study of Tucidinostat in Combination With R-CHOP in Patients With Newly Diagnosed Double-Expressor DLBCL
Role: lead
A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients
Role: lead
Chiauranib in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma
Role: lead
Chiauranib Plus PD-1 Inhibitor, Albumin-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Role: lead
Pilot Bioequivalence Study of Chiglitazar/Metformin Extended-Release Tablets
Role: lead
Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype
Role: lead
A Study to Evaluate the Efficacy and Safety of CS32582 in Participants With Moderate to Severe Plaque Psoriasis
Role: lead
Safety, Pharmacokinetics and Preliminary Efficacy of CS231295 in Advanced Solid Tumors
Role: lead
Chiauranib for Advanced or Unresectable Soft Tissue Sarcoma(STS)
Role: lead
A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC
Role: lead
A Study of AK104 in Combination With Chiauranib in Patients With Extensive Stage Small Cell Lung Cancer
Role: collaborator
VCA Regimen Followed by D-MAG Regimen on the Treatment of Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
Role: collaborator
Phase 3 Clinical Study of Chiauranib Capsule in Patients With Small-cell Lung Cancer
Role: lead
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic Profiles and Food Effect of CS32582 Capsules
Role: lead
Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer
Role: lead